Trial · NCT04079712
Adverse events129
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 129
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 6 | 17 | |
| other | Sinus bradycardia | Cardiac disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 3 | 17 | |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Hearing impaired | Ear and labyrinth disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Adrenal insufficiency | Endocrine disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Hyperthyroidism | Endocrine disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 3 | 17 | |
| other | Hypothyroidism | Endocrine disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 5 | 17 | |
| other | Dry eye | Eye disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Vision Changes | Eye disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Abdominal distension | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 6 | 17 | |
| other | Anal pain | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Ascites | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 2 | 17 | |
| other | Bloating | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 2 | 17 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 5 | 17 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 9 | 17 | |
| other | Dry mouth | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 2 | 17 | |
| other | Dyspepsia | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Dysphagia | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 | |
| other | Flatulence | Gastrointestinal disorders | Treatment (Cabozantinib S-malate, Nivolumab, Ipilimumab) | 1 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04079712/events